Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chandan Takkar, Tareq Nassar & Wajeh Qunibi. (2021) An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia. Expert Opinion on Pharmacotherapy 22:1, pages 19-28.
Read now
Read now
Murray Epstein & Bertram Pitt. (2016) Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opinion on Pharmacotherapy 17:10, pages 1435-1448.
Read now
Read now
Articles from other publishers (43)
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, Michel Burnier, Guido Grassi, Andrzej Januszewicz, Maria Lorenza Muiesan, Konstantinos Tsioufis, Enrico Agabiti-Rosei, Engi Abd Elhady Algharably, Michel Azizi, Athanase Benetos, Claudio Borghi, Jana Brguljan Hitij, Renata Cifkova, Antonio Coca, Veronique Cornelissen, J. Kennedy Cruickshank, Pedro G. Cunha, A.H. Jan Danser, Rosa Maria de Pinho, Christian Delles, Anna F. Dominiczak, Maria Dorobantu, Michalis Doumas, María S. Fernández-Alfonso, Jean-Michel Halimi, Zoltán Járai, Bojan Jelaković, Jens Jordan, Tatiana Kuznetsova, Stephane Laurent, Dragan Lovic, Empar Lurbe, Felix Mahfoud, Athanasios Manolis, Marius Miglinas, Krzystof Narkiewicz, Teemu Niiranen, Paolo Palatini, Gianfranco Parati, Atul PathakAlexandre Persu, Jorge Polonia, Josep Redon, Pantelis Sarafidis, Roland Schmieder, Bart Spronck, Stella Stabouli, George Stergiou, Stefano Taddei, Costas Thomopoulos, Maciej Tomaszewski, Philippe Van de Borne, Christoph Wanner, Thomas Weber, Bryan Williams, Zhen-Yu Zhang & Sverre E. Kjeldsen. (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. Journal of Hypertension 41:12, pages 1874-2071.
Crossref
Crossref
Yuan-Ching Liao, Mei-Yao Wu, Yu-Chuen Huang, Che-Yi Chou & Hung-Rong Yen. (2023) Effectiveness of Chinese herbal medicine compared with angiotensin II receptor blockers in patients with diabetic kidney disease: A hospital-based matched cohort study. Journal of Traditional and Complementary Medicine.
Crossref
Crossref
Rakesh Dattani, Zia Ul-Haq, Moulesh Shah, Gabrielle Goldet, Lord Ara Darzi, Hutan Ashrafian, Tahereh Kamalati, Andrew H. Frankel & Frederick W.K. Tam. (2023) Association and progression of multi-morbidity with Chronic Kidney Disease stage 3a secondary to Type 2 Diabetes Mellitus, grouped by albuminuria status in the multi-ethnic population of Northwest London: A real-world study. PLOS ONE 18:8, pages e0289838.
Crossref
Crossref
David Massicotte-Azarniouch, Mark Canney, Manish M. Sood & Gregory L. Hundemer. (2023) Managing Hyperkalemia in the Modern Era: A Case-Based Approach. Kidney International Reports 8:7, pages 1290-1300.
Crossref
Crossref
Abiy Agiro, Alpesh N. Amin, Erin E. Cook, Fan Mu, Jingyi Chen, Pooja Desai, Yemmie Oluwatosin & Charles V. PollackJr.Jr.. (2023) Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study. Advances in Therapy 40:6, pages 2886-2901.
Crossref
Crossref
Panagiotis Theofilis, Aikaterini Vordoni, Nikos Nakas, Athanasios Kotsakis, Athanasios Kranidis, Ioanna Makryniotou & Rigas G. Kalaitzidis. (2023) Prognostic Significance of Risk Factors and Biomarkers in Patients
Hospitalized for Cardiorenal Syndromes: A Pilot Study. Current Medicinal Chemistry 30:4, pages 492-507.
Crossref
Crossref
Chen Tang, Xin-Yan Wen, Ji-Cheng Lv, Su-Fang Shi, Xu-Jie Zhou, Li-Jun Liu & Hong Zhang. (2023) Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis. American Journal of Nephrology 54:5-6, pages 234-244.
Crossref
Crossref
L. Parker Gregg, Peter A. Richardson, Michael A. Herrera, Julia M. Akeroyd, Shehrezade A. Jafry, Glenn T. Gobbel, Sheena Wydermyer, Jennifer Arney, Adriana Hung, Michael E. Matheny, Salim S. Virani & Sankar D. Navaneethan. (2023) Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. American Journal of Nephrology 54:3-4, pages 126-135.
Crossref
Crossref
Hongru Ren, Silvia J Leon, Reid Whitlock, Claudio Rigatto, Paul Komenda, Clara Bohm, David Collister & Navdeep Tangri. (2022) Prescription patterns of sodium and calcium polystyrene sulfonate in patients with hyperkalemia and chronic kidney disease receiving RAAS inhibitors. Clinical Kidney Journal 15:9, pages 1713-1719.
Crossref
Crossref
Kun Kim, Josefine Fagerström, Gengshi Chen, Zoya Lagunova, Hans Furuland & Phil McEwan. (2022) Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrology 23:1.
Crossref
Crossref
Silvia J. Leon, Reid Whitlock, Claudio Rigatto, Paul Komenda, Clara Bohm, Ewa Sucha, Sarah E. Bota, Meltem Tuna, David Collister, Manish Sood & Navdeep Tangri. (2022) Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study. American Journal of Kidney Diseases 80:2, pages 164-173.e1.
Crossref
Crossref
Antonio Santoro, Valentina Perrone, Elisa Giacomini, Diego Sangiorgi, Davide Alessandrini & Luca Degli Esposti. (2021) Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. Journal of Nephrology 35:2, pages 463-472.
Crossref
Crossref
Eleonora Riccio, Ivana Capuano, Pasquale Buonanno, Michele Andreucci, Michele Provenzano, Maria Amicone, Manuela Rizzo & Antonio Pisani. (2022) RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study. Frontiers in Cardiovascular Medicine 9.
Crossref
Crossref
Dingwei Dai, Ajay Sharma, Paula J Alvarez & Steven D Woods. (2022) Multiple comorbid conditions and healthcare resource utilization among adult patients with hyperkalemia: A retrospective observational cohort study using association rule mining. Journal of Multimorbidity and Comorbidity 12, pages 263355652210988.
Crossref
Crossref
Toby J L Humphrey, Glen James, Eric T Wittbrodt, Donna Zarzuela & Thomas F Hiemstra. (2021)
Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400
000 patients from the UK Clinical Practice Research Datalink (CPRD)
. Clinical Kidney Journal 14:10, pages 2203-2212.
Crossref
Crossref
Carl P Walther, Wolfgang C Winkelmayer, Peter A Richardson, Salim S Virani & Sankar D Navaneethan. (2021) Renin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 36:10, pages 1893-1899.
Crossref
Crossref
Labib AL-Musawe, Carla Torre, Jose Pedro Guerreiro, Antonio Teixeira Rodrigues, Joao Filipe Raposo, Helder Mota-Filipe & Ana Paula Martins. (2021) Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution. European Journal of Clinical Pharmacology 77:9, pages 1397-1407.
Crossref
Crossref
Rhys Williams, Alexander James, Moira Ashton, Sian Vaughan & Aaron Wong. (2021) Use of sodium zirconium cyclosilicate for up-titration of renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure: a case series. European Heart Journal - Case Reports 5:8.
Crossref
Crossref
Ian E. McCoy, Jialin Han, Maria E. Montez-Rath & Glenn M. Chertow. (2021) Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. Mayo Clinic Proceedings 96:8, pages 2114-2122.
Crossref
Crossref
Sriram Sriperumbuduri, Eric McArthur, Gregory L. Hundemer, Mark Canney, Navdeep Tangri, Silvia J. Leon, Sara Bota, Ann Bugeja, Ayub Akbari, Greg Knoll & Manish M. Sood. (2021) Initial and Recurrent Hyperkalemia Events in Patients With CKD in Older Adults: A Population-Based Cohort Study. Canadian Journal of Kidney Health and Disease 8, pages 205435812110174.
Crossref
Crossref
Sai Prasad N. Iyer, Lawrence Lee & Lingyun Li. (2020)
Pharmacodynamic effects of the K
+
binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
. Physiological Reports 8:18.
Crossref
Crossref
Nihar R. Desai, Christopher G. Rowan, Paula J. Alvarez, Jeanene Fogli & Robert D. Toto. (2020) Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. PLOS ONE 15:1, pages e0226844.
Crossref
Crossref
Marc Evans, Eirini Palaka, Hans Furuland, Hayley Bennett, Cecilia Linde, Lei Qin, Phil McEwan & Ameet Bakhai. (2019) The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology 20:1.
Crossref
Crossref
Stefano Bianchi & Giuseppe Regolisti. (2019) Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia. Nephrology Dialysis Transplantation 34:Supplement_3, pages iii51-iii61.
Crossref
Crossref
Lara Belmar Vega, Emilio Rodrigo Galabia, Jairo Bada da Silva, Marta Bentanachs González, Gema Fernández Fresnedo, Celestino Piñera Haces, Rosa Palomar Fontanet, Juan Carlos Ruiz San Millán & Ángel Luis Martín de Francisco. (2019) Epidemiology of hyperkalemia in chronic kidney disease. Nefrología (English Edition) 39:3, pages 277-286.
Crossref
Crossref
Lara Belmar Vega, Emilio Rodrigo Galabia, Jairo Bada da Silva, Marta Bentanachs González, Gema Fernández Fresnedo, Celestino Piñera Haces, Rosa Palomar Fontanet, Juan Carlos Ruiz San Millán & Ángel Luis Martín de Francisco. (2019) Epidemiología de la hiperpotasemia en la enfermedad renal crónica. Nefrología 39:3, pages 277-286.
Crossref
Crossref
Shilpa Vijayakumar, Javed Butler & Stefan D Anker. (2019) New treatments for hyperkalaemia: clinical use in cardiology. European Heart Journal Supplements 21:Supplement_A, pages A41-A47.
Crossref
Crossref
Shilpa Vijayakumar, Javed Butler & George L Bakris. (2019) Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia. European Heart Journal Supplements 21:Supplement_A, pages A20-A27.
Crossref
Crossref
Oyunbileg Magvanjav, Rhonda M. Cooper‐DeHoff, Caitrin W. McDonough, Yan Gong, Mark S. Segal, William R. Hogan & Julie A. Johnson. (2018) Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. The Journal of Clinical Hypertension 21:1, pages 91-101.
Crossref
Crossref
Robert A. Kloner, Coleman Gross, Jinwei Yuan, Ansgar Conrad & Pablo E. Pergola. (2018) Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors. Journal of Cardiovascular Pharmacology and Therapeutics 23:6, pages 524-531.
Crossref
Crossref
Maria Tamargo & Juan Tamargo. (2018) New potassium binders reduce the risk of hyperkalaemia in patients treated with renin–angiotensin–aldosterone system inhibitors. European Heart Journal - Cardiovascular Pharmacotherapy 4:4, pages 193-194.
Crossref
Crossref
Angelo Karaboyas, Hairong Xu, Hal Morgenstern, Francesco Locatelli, Michel Jadoul, Kosaku Nitta, Indranil Dasgupta, Francesca Tentori, Friedrich K. Port & Bruce M. Robinson. (2018) DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney International 94:3, pages 589-598.
Crossref
Crossref
Saibal Das, Jayanta Kumar Dey, Sumalya Sen & Rishav Mukherjee. (2017) Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis. Journal of Pharmacy Practice 31:1, pages 6-17.
Crossref
Crossref
Juan Tamargo, Ricardo Caballero & Eva Delpón. (2018) New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. Cardiovascular Drugs and Therapy 32:1, pages 99-119.
Crossref
Crossref
Deborah J. Clegg, Michael Cody & Biff F. Palmer. (2017) Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia. Mayo Clinic Proceedings 92:8, pages 1248-1260.
Crossref
Crossref
Ghassan Bandak, Yingying Sang, Alessandro Gasparini, Alex R. Chang, Shoshana H. Ballew, Marie Evans, Johan Arnlov, Lars H. Lund, Lesley A. Inker, Josef Coresh, Juan‐Jesus Carrero & Morgan E. Grams. (2017) Hyperkalemia After Initiating Renin–Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. Journal of the American Heart Association 6:7.
Crossref
Crossref
Pablo E. Pergola, David M. Spiegel, Suzette Warren, Jinwei Yuan & Matthew R. Weir. (2017) Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study. American Journal of Nephrology 46:4, pages 323-332.
Crossref
Crossref
Ruth F. Dubin & Sanjiv J. Shah. (2016) Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes?. Current Heart Failure Reports 13:3, pages 132-139.
Crossref
Crossref
Murray Epstein. (2016) Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney International Supplements 6:1, pages 20-28.
Crossref
Crossref
David A. Bushinsky, Gordon H. Williams, Bertram Pitt, Matthew R. Weir, Mason W. Freeman, Dahlia Garza, Yuri Stasiv, Elizabeth Li, Lance Berman & George L. Bakris. (2015) Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney International 88:6, pages 1427-1433.
Crossref
Crossref
Bertram Pitt, George L. Bakris, David A. Bushinsky, Dahlia Garza, Martha R. Mayo, Yuri Stasiv, Heidi Christ‐Schmidt, Lance Berman & Matthew R. Weir. (2015)
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on
RAAS
inhibitors
. European Journal of Heart Failure 17:10, pages 1057-1065.
Crossref
Crossref
Matthew R. Weir, George L. Bakris, David A. Bushinsky, Martha R. Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ-Schmidt, Lance Berman & Bertram Pitt. (2015) Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. New England Journal of Medicine 372:3, pages 211-221.
Crossref
Crossref
Eylem Eliacik, Tolga Yildirim, Ugur Sahin, Cemal Kizilarslanoglu, Umit Tapan, Aysun Aybal-Kutlugun, Gulsen Hascelik & Mustafa Arici. (2015) Potassium Abnormalities in Current Clinical Practice: Frequency, Causes, Severity and Management. Medical Principles and Practice 24:3, pages 271-275.
Crossref
Crossref